Regenerative Medicine News & Intelligence Hub
JAX will use the funding to study how a genetic variant affects the disease and potentially standardize and characterize human cell models for broader research.
Cell and gene therapies are advancing quickly, but the systems needed to deliver them...
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed...
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell...
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a...
The trial found no significant difference in pain or function outcomes between bone marrow...
Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal...
NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up...
What appeared to be a potential stem cell breakthrough is slowly being torn apart...
What can the world learn from Japan’s regenerative medicine laws? We sat down with...
The Australian biotech company is hoping to tackle aGvHD in Europe, which appears to have twice as many cases as the USA.
Syntax is bringing its Cellgorithm cell-therapy discovery platform to the table, while Mayo Clinic will provide expertise in pancreatic biology and functional testing for preclinical diabetes.
JAX will use the funding to study how a genetic variant affects the disease and potentially standardize and characterize human cell models for broader research.
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
The automated CDMO is hoping to reduce America's reliance on foreign biomanufacturing for advanced therapies.
The Living Knee project is hoping to replace traditional knee replacements, expected to begin Phase 1 trials around 2028.
Published in the Journal of Nanobiotechnology, the iPSC-derived therapy delivers BDNF mRNA to injured spinal tissue, improving motor recovery in preclinical studies.
Building on work at the University of Wisconsin-Madison, the Australian biotech company expects to release data from its Phase 3 iPSC-derived MSC KOA & Phase 2 Graft-vs-Host-Disease trials in the coming months.
Made Scientific will use RoosterBio's off-the-shelf MSCs, MSC expansion media, EV collection media, and related bioprocess expertise into its GMP operations.
The 38 projects include work in diabetes, cancer, Parkinson's disease, stroke, sickle cell disease, chronic pain, and cardiovascular, bone, blood, digestive, and neurological disorders
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The site will also serve as the company's new headquarters, expanding its services in iPSC-based drug discovery, regenerative medicine, and cell therapy work.
The company is expanding its preclinical work on acute respiratory syndrome to investigate whether its fibroblasts may help with deadly lung inflammation, vascular leakage, and tissue damage.
The partnership hopes to speed up the scalable development of SC451 for type 1 diabetes by standardizing treatment protocols, improving clinical delivery and post-care, and preparing the therapy for broader use across...
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
